Prednisolone (DB00860): A Comprehensive Monograph on its Pharmacology, Clinical Utility, and Safety Profile

I. Introduction: The Enduring Significance of Prednisolone in Modern Therapeutics

Prednisolone is a synthetic glucocorticoid that has served as a cornerstone of anti-inflammatory and immunosuppressive therapy for nearly seven decades. First discovered and approved for medical use in 1955, it represents a pivotal advancement in the therapeutic application of corticosteroids.[1] Structurally, it is the active metabolite of the prodrug prednisone, to which it is converted in the liver, and is a derivative of the endogenous hormone cortisol.[2] Its development provided clinicians with a potent tool to manage a previously intractable spectrum of inflammatory and autoimmune diseases.

Classified as a corticosteroid with predominant glucocorticoid activity and low mineralocorticoid effects, prednisolone's therapeutic utility is exceptionally broad.[1] Its fundamental importance in global health is underscored by its inclusion on the World Health Organization's List of Essential Medicines, a recognition reserved for medications considered most effective and safe to meet the most important needs in a health system.[1] Despite its age, its clinical relevance has not waned. In 2022, it was the 136th most commonly prescribed medication in the United States, accounting for over 4 million prescriptions.[1] This sustained high volume of use in an era of targeted biologics and novel immunomodulators speaks to its unique and enduring therapeutic position.

The core therapeutic role of prednisolone is to act as a powerful anti-inflammatory and immunosuppressive agent.[4] It achieves this by mimicking the effects of endogenous cortisol, thereby modulating the body's immune response to diverse stimuli and effectively reducing the cardinal signs of inflammation: swelling, redness, heat, and pain, as well as associated symptoms like itching.[3] This broad mechanism of action makes it an indispensable treatment for a vast array of conditions, including severe allergies, chronic autoimmune disorders like rheumatoid arthritis and lupus, inflammatory bowel disease, certain hematologic and neoplastic conditions, and the prevention of organ transplant rejection.[1] The continued reliance on this legacy drug demonstrates that its potent, rapid, and cost-effective action fills a critical therapeutic niche that newer, more specific, and often more expensive agents have yet to fully replace. Its utility is not diminishing but is instead being continuously reaffirmed and even repurposed within the context of modern combination therapies.

II. Chemical Identity and Physicochemical Properties

Drug Identification

• Name: Prednisolone [1]
• Type: Small Molecule [7]
• DrugBank ID: DB00860 [2]
• CAS Number: 50-24-8 [2]

Chemical Structure and Formula

Prednisolone is a C21-steroid with a well-defined chemical structure.

• Molecular Formula: C21​H28​O5​ [2]
• Molecular Weight: Average values reported as 360.44 g/mol, 360.444 g/mol, and 360.45 g/mol.[6]
• IUPAC Name: (8S,9S,10R,11S,13S,14S,17R)−11,17−dihydroxy−17−(2−hydroxyacetyl)−10,13−dimethyl−7,8,9,11,12,14,15,16−octahydro−6H−cyclopenta[a]phenanthren−3−one.[2]
• Structural Description: Prednisolone is chemically defined as prednisone in which the oxo group at the C-11 position has been reduced to a beta-hydroxy group. This structural change transforms the inert prodrug (prednisone) into the active glucocorticoid. It is systematically classified as an 11beta-hydroxy steroid, a 21-hydroxy steroid, a 17alpha-hydroxy steroid, a 20-oxo steroid, and a 3-oxo-Delta(1),Delta(4)-steroid, and is functionally related to a Delta(1)-progesterone.[2]

Synonyms and Alternate Names

Reflecting its long history and global use, prednisolone is known by numerous synonyms and alternate chemical names. These include, but are not limited to, Metacortandralone, Meticortelone, Deltacortril, delta-hydrocortisone, delta(1)-Dehydrocortisol, and the National Cancer Institute (NCI) identifiers NSC-9900 and NSC-9120.[6]

The following table consolidates the key chemical and database identifiers for prednisolone, providing a comprehensive reference for researchers and database cross-referencing.

Identifier Type	Code/Value	Source(s)
CAS Number	50-24-8	2
DrugBank ID	DB00860	7
Molecular Formula	C21​H28​O5​	2
IUPAC Name	(8S,9S,10R,11S,13S,14S,17R)−11,17−dihydroxy−17−(2−hydroxyacetyl)−10,13−dimethyl−7,8,9,11,12,14,15,16−octahydro−6H−cyclopenta[a]phenanthren−3−one	2
InChIKey	OIGNJSKKLXVSLS-VWUMJDOOSA-N	2
SMILES	C[C@]12CC@@HO
FDA UNII	9PHQ9Y1OLM
ChEBI ID	CHEBI:8378
ChEMBL ID	CHEMBL131
KEGG ID	C07369, D00472
PubChem CID	5755
RxCUI	8638
HMDB ID	HMDB0014998
NCI Thesaurus Code	C769

III. Comprehensive Pharmacological Profile

A. Pharmacodynamics: Molecular Mechanisms of Action

The profound anti-inflammatory and immunosuppressive effects of prednisolone are mediated through a well-characterized molecular pathway involving genomic and non-genomic actions.

Receptor Binding and Agonism

Prednisolone functions as a potent agonist for the nuclear glucocorticoid receptor (GCR) and, to a lesser degree, the mineralocorticoid receptor (MR). Its binding affinity is highly selective; studies have demonstrated dissociation constants (

Ki​) of 2.4 nM for the GCR and 37 nM for the MR, compared to much weaker affinities for progesterone (>5,000 nM), androgen (2,762 nM), and estrogen (>1,000 nM) receptors. This selectivity ensures that its primary effects are mediated through the glucocorticoid pathway.

Cellular Pathway of Action

The mechanism begins with prednisolone's entry into the target cell and culminates in the alteration of gene expression.

1. Cellular Entry: As a lipophilic steroid molecule, prednisolone readily diffuses across the plasma membrane of target cells.
2. Cytoplasmic Complex Formation: Once inside the cytoplasm, prednisolone binds to its cognate GCR, which is part of a multiprotein complex that includes chaperone proteins like heat shock proteins (Hsp90, Hsp70). This binding event induces a conformational change in the GCR, causing the dissociation of these chaperone proteins.
3. Nuclear Translocation: The now-activated glucocorticoid/GCR complex is free to translocate from the cytoplasm into the cell nucleus. This process is relatively rapid, occurring within approximately 20 minutes of the initial binding event.
4. Gene Regulation: Inside the nucleus, the activated complex dimerizes and binds to specific DNA sequences known as Glucocorticoid Response Elements (GREs), which are located in the promoter regions of target genes.

Transcriptional Effects (Transactivation and Transrepression)

The interaction of the GC/GCR complex with DNA leads to two primary outcomes: transactivation and transrepression.

• Transactivation: The complex binds to positive GREs, which initiates the transcription of genes encoding anti-inflammatory proteins. Key examples include annexin A1 (also known as lipocortin-1) and Interleukin-10 (IL-10). Annexin A1 is particularly important as it inhibits the enzyme phospholipase A2.
• Transrepression: The complex suppresses the expression of pro-inflammatory genes. This can occur through direct binding to negative GREs or, more commonly, through protein-protein interactions that interfere with the activity of pro-inflammatory transcription factors. Prednisolone potently inhibits key factors such as Nuclear Factor-kappa B (NF-κB) and Activator Protein 1 (AP-1), preventing them from driving the production of inflammatory mediators.

Downstream Anti-inflammatory and Immunosuppressive Effects

The genomic changes triggered by prednisolone result in a broad cascade of anti-inflammatory and immunosuppressive events.

• Inhibition of Inflammatory Mediators: By upregulating annexin A1, prednisolone inhibits phospholipase A2 (PLA2), the enzyme responsible for releasing arachidonic acid from cell membranes. This blockade cuts off the supply of the precursor for the synthesis of potent pro-inflammatory mediators, including prostaglandins and leukotrienes. The inhibition of NF-κB and AP-1 further reduces the production of inflammatory cytokines (e.g., TNF-α, IL-1, IL-6) and chemokines.
• Effects on Immune Cells: Prednisolone significantly alters the function and trafficking of immune cells. It suppresses the immune system by decreasing the activity and volume of circulating lymphocytes (both T- and B-cells), monocytes, and eosinophils. It specifically inhibits T-lymphocyte proliferation by reducing the production of IL-2, a critical T-cell growth factor. Concurrently, it increases the number of circulating neutrophils by inhibiting their apoptosis and promoting their release from the bone marrow.
• Other Mechanisms: Prednisolone also contributes to inflammation control by stabilizing lysosomal membranes, which prevents the release of destructive proteolytic enzymes into tissues, and by reversing the increased capillary permeability that is a hallmark of acute inflammation.

The profound efficacy of prednisolone is inextricably linked to its extensive and often severe side-effect profile. This is not a flaw in the drug's design but a direct and unavoidable consequence of its fundamental mechanism. Because glucocorticoid receptors are found in almost all tissues and organ systems, the drug's action is not targeted to a specific site of inflammation but is systemic. It simultaneously affects bone metabolism, central nervous system function, skin integrity, endocrine balance, and cardiovascular regulation. This directly explains why the list of adverse effects is so long and diverse, spanning from psychiatric disturbances and osteoporosis to diabetes and Cushing's syndrome. The therapeutic benefit achieved in one system comes at the predictable, mechanism-based cost of physiological disruption in others, presenting a core clinical management challenge.

B. Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of prednisolone explains its clinical use patterns, including its dosing schedule and interactions with other drugs.

The Prednisone-Prednisolone Prodrug System

Prednisolone is the active form of the drug. It can be administered directly or be produced in the body from its prodrug, prednisone.

• Prednisone is a biologically inert compound that is rapidly and efficiently converted in the liver to the active metabolite, prednisolone. This conversion is catalyzed by the enzyme 11-β-hydroxysteroid dehydrogenase.
• This enzymatic reaction is reversible. The forward reaction (prednisone to prednisolone) is favored in the liver and fat cells, ensuring activation of the drug after oral administration of prednisone. The reverse reaction (prednisolone to prednisone) can occur in other tissues, such as the kidney and colon. For most clinical purposes, prednisone and prednisolone are considered therapeutically equivalent and interchangeable.

Absorption and Bioavailability

Following oral administration, prednisolone is well absorbed from the gastrointestinal tract.

• Peak plasma concentrations are typically reached within 1 to 2 hours for immediate-release tablet formulations. Oral solutions may be absorbed faster, producing a 14% higher peak plasma level that occurs 20% more quickly than with tablets.
• The oral bioavailability is high, generally reported to be in the range of 70-80%, with some studies suggesting it approaches 100% of an equivalent intravenous dose.

Distribution

Once absorbed, prednisolone distributes throughout the body.

• It is extensively bound to plasma proteins, with 70-90% of the drug bound, primarily to albumin. In patients with hypoalbuminemia (e.g., due to liver disease), the fraction of unbound, active drug is higher, increasing the risk of side effects.
• The volume of distribution is dose-dependent, increasing from approximately 29.3 L at a dose of 0.15 mg/kg to 44.2 L at 0.30 mg/kg, indicating greater tissue penetration at higher doses. Due to its lipophilic nature, it readily crosses cell membranes and can also cross the placenta and be excreted into breast milk.

Metabolism

Prednisolone undergoes extensive metabolism, primarily in the liver.

• Key metabolic pathways include hydrogenation to form 20α- and 20β-dihydro-prednisolone metabolites and hydroxylation to form 6β-hydroxy-prednisolone. The hydroxylation step is mediated by the cytochrome P450 enzyme CYP3A4.
• Prednisolone itself is an inducer of CYP3A4 expression. This means that chronic use can increase the rate of its own metabolism and that of other drugs that are substrates for this enzyme. Conversely, co-administration with strong CYP3A4 inhibitors, such as the antifungal drug ketoconazole, can significantly decrease prednisolone clearance and raise its plasma concentrations by about 50%, thereby increasing the risk of adverse effects.

Excretion

The metabolites of prednisolone are primarily eliminated from the body via the kidneys.

• It is excreted in the urine, mainly as inactive glucuronide and sulphate conjugates. Only a small fraction (2-5%) of a dose is excreted as unchanged prednisone.
• A critical distinction exists between the drug's plasma half-life and its biological half-life. The plasma half-life (t1/2​), which reflects the time it takes for the drug concentration in the blood to decrease by half, is relatively short, ranging from 2 to 4 hours. However, the biological half-life, which reflects the duration of its physiological effects, is much longer, estimated at 12 to 36 hours. This disconnect is fundamental to understanding its clinical use. The drug's therapeutic action is not dependent on its continuous presence in the plasma but rather on the downstream consequences of its brief interaction with nuclear receptors—namely, the synthesis of new anti-inflammatory proteins and the repression of pro-inflammatory ones. These newly synthesized proteins and the suppression of gene expression persist long after the drug itself has been cleared from the bloodstream. This explains why once-daily dosing is not only effective but is the standard clinical practice, as it is sufficient to trigger a full day's worth of biological effect. It also provides the rationale for alternate-day therapy as a strategy to minimize long-term side effects by allowing for partial recovery of the body's own systems on the "off" day.

IV. Clinical Applications and Therapeutic Efficacy

A. Approved Therapeutic Indications: A Multi-System Review

The potent anti-inflammatory and immunosuppressive properties of prednisolone make it effective for an exceptionally wide range of diseases across virtually every organ system. The FDA-approved indications for modern formulations, such as Orapred ODT, provide a structured framework for its use.

• Allergic Conditions: For severe or incapacitating allergic states intractable to conventional treatment, including atopic dermatitis, drug hypersensitivity reactions, serum sickness, and seasonal or perennial allergic rhinitis.
• Dermatologic Diseases: A variety of corticosteroid-responsive skin diseases, such as pyoderma gangrenosum and severe urticaria.
• Endocrine Conditions: Used as replacement therapy in primary or secondary adrenocortical insufficiency (Addison's disease), where the body does not produce enough of its own steroids. It is also indicated for congenital adrenal hyperplasia and for managing cancer-associated hypercalcemia.
• Gastrointestinal Diseases: To induce remission during acute episodes of inflammatory bowel diseases, including Crohn's Disease and ulcerative colitis.
• Hematologic Disorders: For immune-mediated blood disorders such as acquired (autoimmune) hemolytic anemia, idiopathic thrombocytopenic purpura (ITP) in adults, and pure red cell aplasia.
• Neoplastic Conditions: As a component of chemotherapy regimens for palliative management of certain cancers, particularly acute leukemias and aggressive lymphomas in both adults and children.
• Nervous System Disorders: For managing acute exacerbations of multiple sclerosis and for reducing cerebral edema associated with primary or metastatic brain tumors.
• Ophthalmic Diseases: A cornerstone in ophthalmology for a wide range of inflammatory and allergic eye conditions. It is used topically (as eye drops) for uveitis, allergic conjunctivitis, keratitis, and to reduce inflammation following surgery or corneal injuries.
• Organ Transplantation: As a critical component of immunosuppressive regimens to prevent acute or chronic rejection of solid organ transplants.
• Pulmonary Diseases: For respiratory conditions including acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD), aspiration pneumonitis, and as an adjunct in treating fulminating or disseminated pulmonary tuberculosis (concurrently with appropriate anti-tuberculous chemotherapy).
• Rheumatic Disorders: For a multitude of autoimmune and inflammatory rheumatic conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, systemic lupus erythematosus (lupus), Sjögren's syndrome, and various forms of vasculitis.

B. Analysis of Off-Label and Investigational Uses

Prednisolone is frequently prescribed for indications, patient populations, or dosages not formally listed on the FDA-approved product label, a common practice known as off-label use. It is important to recognize the distinction between regulatory status and clinical practice. Many uses technically considered "off-label" are, in fact, well-established standards of care supported by decades of clinical evidence and professional guidelines. For instance, while some sources may classify the use of prednisolone for inflammation, immune-mediated diseases, Addison's disease, or neoplasia as "off-label," these are precisely the core therapeutic areas where the drug is most widely and effectively used. This apparent paradox arises because an FDA label is specific to the data submitted for a particular branded formulation (e.g., Orapred ODT), whereas the clinical use of the drug class is guided by a much broader body of evidence.

Key off-label and investigational applications include:

• Bell's Palsy: A common and evidence-supported off-label use involves a course of high-dose oral prednisolone to reduce facial nerve inflammation and improve outcomes. A typical regimen is 60 mg per day for five days, followed by a five-day taper.
• IgA Nephropathy: Emerging evidence suggests that prednisolone may have a protective effect in patients with this form of chronic kidney disease. A Phase 3 clinical trial is currently underway to formally evaluate its efficacy in this population.
• Hand Osteoarthritis: The role of prednisolone in hand OA appears to depend heavily on dose and the presence of inflammation. One randomized controlled trial (RCT) found that a 6-week course of 10 mg/day was effective and safe in patients with painful hand OA who had clear signs of synovial inflammation. In contrast, another RCT found that a lower dose of 5 mg/day for 4 weeks was not an effective analgesic, suggesting that an adequate anti-inflammatory dose is necessary and that patient selection is critical.
• Recurrent Pregnancy Loss: The potential for prednisolone to modulate the maternal immune system has led to its investigation as a treatment for unexplained recurrent pregnancy loss. A large, multicenter RCT (the PREMI-study) is currently ongoing to determine if early pregnancy administration of prednisolone improves the live birth rate compared to placebo.
• Veterinary Medicine: Prednisolone is used extensively in veterinary medicine, almost entirely on an off-label basis. It is particularly preferred over prednisone in cats, as felines have a limited capacity to metabolize the prodrug into its active form. It is prescribed for a wide range of inflammatory conditions, immune-mediated diseases, severe allergies, and as part of chemotherapy protocols in both dogs and cats.

V. Dosage, Formulations, and Principles of Administration

A. Available Pharmaceutical Formulations and Brand Names

Prednisolone is available in a variety of formulations to accommodate different clinical needs, patient populations, and routes of administration. It is widely available as a generic drug and under numerous brand names globally.

Formulation Type	Available Strengths	Example Brand Names (Region)	Source(s)
Oral Tablet	5 mg, 10 mg, 20 mg, 50 mg	Millipred (US), Deltacortril (UK), Pevanti (UK)
Orally Disintegrating Tablet (ODT)	10 mg, 15 mg, 30 mg	Orapred ODT (US)
Oral Solution / Syrup	5 mg/5 mL, 10 mg/5 mL, 15 mg/5 mL, 20 mg/5 mL, 25 mg/5 mL, 30 mg/5 mL	Pediapred (US), Prelone (US), Flo-Pred (US, discontinued)
Tablet Dose Pack	5 mg tablets in 21-count or 48-count tapered packs	Millipred DP (US)
Ophthalmic Suspension / Eye Drops	1%	Pred Forte (Global), Omnipred (US)
Rectal Enema	Varies	Not specified in sources, but mentioned as a route of administration for ulcerative colitis.
Injectable Solution	Varies	Not specified in sources, but mentioned as available for hospital use.

Globally, the number of brand names is vast, reflecting its widespread use. Many products are also available that combine prednisolone with other active ingredients, such as antibiotics or local anesthetics, for topical use (e.g., Canaural for veterinary ear infections, Scheriproct for hemorrhoids).

B. Principles of Dosing and Therapeutic Regimens

The dosing of prednisolone is not standardized but is highly individualized based on the specific disease, its severity, and the patient's clinical response and tolerance.

• Dose Variability: Initial adult oral doses can range widely, from as low as 5 mg per day for mild conditions to 60 mg per day or higher for severe, acute flares. Pediatric dosing is almost always calculated based on body weight or body surface area, with a common range being 0.1-2 mg/kg/day, depending on the indication. For example, acute asthma in children is often treated with 1-2 mg/kg/day for 3-5 days.
• Administration Guidelines:
• Timing of Dose: To align with the body's natural circadian rhythm of cortisol production and to minimize certain side effects, particularly insomnia, it is strongly recommended that the total daily dose be taken once in the morning, ideally before 9:00 AM. This ensures that exogenous steroid levels are lowest at night.
• Administration with Food: To reduce the risk of gastrointestinal irritation and indigestion, prednisolone should be taken with food or milk.
• Dose Tapering: This is a critical principle of corticosteroid therapy. The body's own production of cortisol is suppressed by exogenous steroids via the hypothalamic-pituitary-adrenal (HPA) axis. If prednisolone is stopped abruptly after more than a few weeks of treatment, the HPA axis cannot recover quickly enough, leading to acute adrenal insufficiency, which can be life-threatening. Therefore, the dose must always be tapered gradually to allow the adrenal glands to resume normal function. The rate of tapering depends on the dose and duration of the initial therapy.
• Special Populations:
• Pregnancy: Prednisolone is generally considered safer than fluorinated corticosteroids (e.g., dexamethasone) during pregnancy because the placenta contains enzymes that metabolize a significant portion of the drug before it reaches the fetus. It is used to treat conditions like antiphospholipid syndrome in pregnant women. However, high doses may be associated with increased risks of hypertension and diabetes, and there may be a slight increase in the risk of cleft palate with first-trimester use.
• Pediatrics: Long-term or high-dose therapy in children and teenagers can suppress linear growth. Therefore, height and weight must be carefully monitored throughout treatment.

VI. In-Depth Safety and Tolerability Profile

The clinical use of prednisolone requires a thorough understanding of its extensive adverse effect profile, which is a direct extension of its potent pharmacological actions. The risk and severity of side effects are closely related to the dose and duration of therapy.

A. Adverse Drug Reactions: A System-Organ Class Analysis

The following table summarizes the adverse effects of prednisolone, organized by system organ class and categorized by general frequency and onset.

System Organ Class	Adverse Reaction	Frequency / Onset	Source(s)
Psychiatric / Neurological	Insomnia, restlessness, anxiety	Common / Short-term
	Mood swings (depression, elation)	Common / Short-term
	Severe depression, psychosis, hallucinations, confusion, memory loss	Uncommon to Rare / Dose-dependent
	Convulsions, raised intracranial pressure (headache, vertigo)	Rare / Dose-dependent
Metabolic / Endocrine	Increased appetite, weight gain	Very Common / Short- to Long-term
	Fluid retention (edema)	Common / Short- to Long-term
	Hyperglycemia, new-onset diabetes, worsening of existing diabetes	Common / Dose-dependent
	Cushing's syndrome (moon face, truncal obesity, buffalo hump)	Common / Long-term
	Adrenal suppression, adrenal crisis upon withdrawal	Common / Long-term or abrupt cessation
	Hypokalemia (low potassium), hypokalemic alkalosis	Uncommon / Dose-dependent
	Menstrual irregularities	Uncommon / Long-term
Gastrointestinal	Indigestion, nausea, abdominal distention	Common / Short-term
	Peptic ulcer, gastrointestinal bleeding, perforation	Uncommon to Rare / Risk increases with NSAIDs
	Pancreatitis	Rare / Serious
Musculoskeletal	Muscle weakness, steroid myopathy	Uncommon / Long-term
	Osteoporosis, increased fracture risk (vertebral compression)	Common / Long-term
	Aseptic necrosis of femoral and humeral heads	Uncommon / Long-term
	Suppression of growth in children	Common / Long-term
Dermatologic	Acne, increased sweating, hirsutism	Common / Long-term
	Skin thinning, fragility, easy bruising, striae, petechiae	Common / Long-term
	Impaired wound healing	Common / Dose-dependent
Cardiovascular	Hypertension (high blood pressure)	Common / Dose-dependent
	Congestive heart failure, cardiac enlargement (in susceptible patients)	Uncommon / Dose-dependent
	Venous thromboembolism	Increased risk, even with short-term use
Ophthalmic	Posterior subcapsular cataracts	Common / Long-term
	Increased intraocular pressure, glaucoma	Common / Dose-dependent
	Exophthalmos (bulging eyes)	Uncommon / Long-term
Immune System	Increased susceptibility to infections, masking of infection signs	Very Common / Dose-dependent
	Reactivation of latent infections (e.g., tuberculosis)	Rare but serious

B. Contraindications, Warnings, and Precautions

• Absolute Contraindications: Prednisolone should not be used in patients with known hypersensitivity to the drug or its components, or in those with systemic fungal infections.
• Warnings and Precautions:
• Infection Risk: The immunosuppressive effects of prednisolone can mask the signs of an infection and increase susceptibility to new or worsening existing infections. Patients should be advised to avoid contact with individuals who have contagious illnesses like chickenpox or measles if they are not immune. Administration of live or live-attenuated vaccines is contraindicated during high-dose corticosteroid therapy, as the vaccine may cause disease.
• HPA Axis Suppression: Prolonged use will suppress the HPA axis. Abrupt withdrawal can lead to an adrenal crisis. All patients on long-term therapy or who have recently stopped should carry a steroid emergency card or wear a medical alert bracelet.
• Cardiovascular and Renal Effects: Corticosteroids can cause fluid retention, electrolyte disturbances, and elevated blood pressure. They should be used with caution in patients with congestive heart failure, recent myocardial infarction, or hypertension.
• Psychiatric Effects: Steroids can induce a range of psychiatric disturbances. Caution is required in patients with a history of emotional instability or psychotic tendencies.
• Pre-existing Conditions: Careful monitoring is required when used in patients with diabetes mellitus (due to hyperglycemia), osteoporosis, peptic ulcer disease, liver disease, or kidney disease.

C. Clinically Significant Drug Interactions

Prednisolone is subject to numerous drug interactions, which can alter its efficacy or increase the risk of toxicity. Over 600 potential interactions have been identified, with more than 80 classified as major.

Interacting Drug/Class	Mechanism of Interaction	Potential Clinical Outcome	Management Recommendation	Source(s)
NSAIDs (e.g., Ibuprofen, Aspirin)	Additive gastrointestinal toxicity	Increased risk of peptic ulceration, GI bleeding, and perforation	Avoid combination if possible. If necessary, use with caution and consider gastroprotective agents (e.g., PPIs).
CYP3A4 Inducers (e.g., Phenytoin, Carbamazepine, Rifampin)	Increased hepatic metabolism of prednisolone via CYP3A4 induction	Decreased plasma concentrations and reduced therapeutic effect of prednisolone	Monitor for reduced efficacy. May require an increased dose of prednisolone.
CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Ritonavir)	Decreased hepatic metabolism of prednisolone via CYP3A4 inhibition	Increased plasma concentrations and increased risk of corticosteroid side effects	Monitor for signs of corticosteroid toxicity. May require a reduced dose of prednisolone.
Potassium-Depleting Diuretics (e.g., Furosemide, Hydrochlorothiazide)	Additive potassium loss	Increased risk of severe hypokalemia, which can lead to cardiac arrhythmias and muscle weakness	Monitor serum potassium levels closely. Potassium supplementation may be necessary.
Warfarin	Variable effect on anticoagulant activity	Prednisolone can either increase or decrease the effect of warfarin, leading to risk of bleeding or thrombosis	Monitor INR/prothrombin time frequently and adjust warfarin dose as needed.
Live Vaccines (e.g., MMR, Varicella, Nasal Flu)	Pharmacodynamic antagonism (immunosuppression)	Diminished vaccine response and increased risk of disseminated infection from the vaccine virus	Avoid administration of live vaccines to patients on immunosuppressive doses of prednisolone.
Fluoroquinolone Antibiotics (e.g., Ciprofloxacin, Levofloxacin)	Unknown, likely additive toxicity	Increased risk of tendon rupture, particularly the Achilles tendon	Use combination with caution, especially in the elderly. Counsel patients on symptoms of tendonitis.
Other Immunosuppressants (e.g., Cyclosporine, Chemotherapy)	Additive immunosuppression	Profoundly increased risk of opportunistic infections	Use combination under specialist supervision. Prophylactic anti-infective therapy may be warranted.

VII. Regulatory and Commercial Landscape

A. Regulatory History and FDA Approval Timeline

Prednisolone has a long regulatory history, reflecting its status as a foundational therapeutic agent.

• Initial Approval: The active drug, prednisolone, was first granted approval by the U.S. Food and Drug Administration (FDA) on June 21, 1955. This followed the approval of its prodrug, prednisone, earlier the same year on February 21, 1955.
• Subsequent Formulation Approvals: The market for prednisolone is mature, but it is not static. There has been continued development aimed at creating more patient-friendly or specialized formulations. This demonstrates a two-tiered market: a low-margin, high-volume segment for standard tablets, and a higher-value segment for innovative or complex formulations. Key later approvals include:
• Prednisolone Sodium Phosphate Oral Solution (NDA #075250): This liquid formulation, useful for pediatric patients and those with difficulty swallowing, was approved on July 12, 2002, for WE Pharmaceuticals, Inc..
• Orapred ODT (prednisolone sodium phosphate orally disintegrating tablets): First approved on June 1, 2006, for BioMarin Pharmaceutical Inc. and Alliant Pharmaceuticals, Inc. This grape-flavored ODT was specifically developed to improve adherence in children being treated for asthma and other inflammatory conditions.
• Flo-Pred (prednisolone acetate oral suspension): This cherry-flavored oral suspension was approved on January 17, 2008, for Taro Pharmaceuticals USA, Inc. It has since been discontinued.
• Prednisolone Acetate Ophthalmic Suspension 1%: Highlighting ongoing activity in complex generics, a version referencing the brand Pred Forte® received FDA approval for Amneal Pharmaceuticals, with a commercial launch planned for the third quarter of 2025.

B. Global Manufacturing and Supply Chain

The manufacturing and supply chain for prednisolone is robust and global, involving numerous companies at both the Active Pharmaceutical Ingredient (API) and finished product levels.

• Active Pharmaceutical Ingredient (API) Manufacturers: The production of the core chemical substance is a specialized process undertaken by a diverse group of companies worldwide. Major players include:
• European Manufacturers: Axplora (through its Farmabios facility in Italy, which specializes in steroids), Pharma Greven GmbH (Germany), and Caesar & Loretz GmbH (Germany) are key European suppliers.
• Asian Manufacturers: A significant portion of the global API supply originates from China and India, with prominent companies including Sinoway industrial Co.,Ltd., Shandong Octagon Chemicals Limited, Envee Drugs Pvt Ltd, Symbiotec Pharmalab, Cipla, and Sun Pharmaceutical.
• Major Pharmaceutical Corporations: Large multinational corporations like Sanofi, Pfizer (through its Pfizer CentreOne division), Teva Pharmaceutical Industries, and GlaxoSmithKline are also major producers of corticosteroid APIs, ensuring a stable global supply.
• Finished Product Manufacturers: A multitude of pharmaceutical companies formulate the API into tablets, solutions, and other dosage forms for distribution.
• Major Generic Manufacturers (U.S. Market): Key suppliers of generic prednisolone and prednisone in the U.S. include Teva Pharmaceuticals, Hikma Pharmaceuticals, Par Pharmaceuticals (part of Endo International), Amneal Pharmaceuticals, Chartwell RX, and Mylan (now part of Viatris).
• Global and Regional Players: Companies with a significant international presence in the prednisolone market include AdvaCare Pharma (with manufacturing in the USA, China, and India), Alliance Pharmaceuticals (UK), Aspen Pharmacare (South Africa), Pfizer, Novartis, and Merck. The UK's NHS lists numerous suppliers for generic prednisolone tablets, highlighting the competitive nature of the market.

VIII. Review of Contemporary Clinical Research

Despite being a well-established drug, prednisolone continues to be the subject of active clinical research. The focus of this research reveals two major trends: first, the repurposing and integration of prednisolone as an essential supportive care drug to enable modern therapies, particularly in oncology; and second, the optimization of its use in traditional inflammatory diseases through refined dosing strategies and improved patient stratification to enhance its benefit-risk ratio.

A. Analysis of Key Completed Clinical Trials

• The GLORIA Trial (Rheumatoid Arthritis in the Elderly): This landmark pragmatic RCT investigated the long-term use of low-dose (5 mg/day) prednisolone as an add-on therapy in patients aged 65 and older with active RA. Over two years, the study demonstrated that prednisolone provided statistically significant and clinically meaningful benefits, reducing disease activity (DAS28 score) by 0.37 points and slowing joint damage progression compared to placebo. This efficacy came with a trade-off: a 24% increased relative risk of adverse events, primarily non-severe infections. The trial concluded that for this specific elderly population, the balance of benefit and harm was favorable, providing crucial evidence to support long-term, low-dose use in a group where it is often avoided.
• The HOPE Trial (Hand Osteoarthritis): This double-blind, placebo-controlled trial addressed the unmet need for effective treatments in painful hand OA. It found that a 6-week course of 10 mg/day prednisolone significantly reduced finger pain compared to placebo in patients who had clinical and ultrasound evidence of synovial inflammation. This result is particularly insightful when contrasted with a separate trial that found a lower dose of 5 mg/day was ineffective. Together, these findings underscore the critical importance of both adequate dosing and patient selection; prednisolone is likely effective in hand OA, but only in the subset of patients with a clear inflammatory component and when used at a sufficient anti-inflammatory dose.
• Dosing in Acute Calcium Pyrophosphate (CPP) Crystal Arthritis: An open-label RCT compared a 10 mg/day dose versus a 30 mg/day dose of prednisolone for acute CPP arthritis (pseudogout). The study found no significant difference between the two doses in the primary outcome of time to complete symptom resolution. While the higher dose led to a faster initial clinical resolution, this difference was not significant after adjusting for confounders. With no difference in safety outcomes, the results suggest that the lower 10 mg dose is as effective as the 30 mg dose, providing a strong rationale for using the lowest effective dose to minimize potential side effects.
• Pharmacokinetics in Childhood-Onset SLE (cSLE): A pharmacokinetic study in young patients with cSLE highlighted a significant challenge in pediatric dosing. Even when doses were adjusted for body weight, there was substantial inter-individual variability in systemic drug exposure (as measured by the area under the curve, AUC), with a coefficient of variation of 58%. This finding suggests that standardized weight-based dosing may lead to under- or over-exposure in some children, potentially compromising efficacy or increasing toxicity. It provides a strong argument for future research into personalized dosing strategies, such as therapeutic drug monitoring, to optimize treatment in this vulnerable population.

B. Overview of Ongoing and Recent Clinical Investigations

The current clinical trial landscape demonstrates prednisolone's evolving role as both a primary therapy and a critical supportive agent.

• Oncology: Prednisolone remains a backbone component in numerous active, large-scale clinical trials for hematologic malignancies. It is not being tested as a novel cure but is being integrated into the most advanced therapeutic regimens. Active trials are evaluating it in combination with newer targeted agents like the BCL-2 inhibitor venetoclax and the menin inhibitor revumenib for relapsed/refractory leukemia. It is also a key part of standard-of-care combination chemotherapy regimens (e.g., R-CHOP) being compared against novel combinations for lymphoma and is used in post-induction therapy for high-risk B-cell acute lymphoblastic leukemia (B-ALL).
• Management of Immune-Related Adverse Events (irAEs): The advent of immune checkpoint inhibitors has revolutionized cancer treatment but has also introduced a new class of toxicities (irAEs). Corticosteroids are the first-line treatment for these irAEs. Post-hoc analyses of major clinical trials (including the CheckMate series) are now providing critical insights into how to use them optimally. A key finding from a large analysis of patients receiving combination immunotherapy was that the peak dose of corticosteroids used to treat an irAE was associated with worse survival outcomes. Patients receiving 1 mg/kg or 2 mg/kg of prednisolone had significantly worse progression-free and overall survival than those receiving 0.5 mg/kg. The cumulative dose, however, was not associated with survival. This suggests that while steroids are necessary, starting with the lowest feasible dose is critical to avoid negatively impacting the efficacy of the cancer immunotherapy.
• Graft-Versus-Host Disease (GVHD): Following allogeneic stem cell transplantation, GVHD is a major cause of morbidity and mortality. Prednisolone is the standard first-line therapy, and several active trials are investigating its use in combination with novel agents like axatilimab (an anti-CSF-1R antibody) and belumosudil (a ROCK2 inhibitor) to improve outcomes in newly diagnosed chronic GVHD.
• Other Investigational Areas: Active research continues to explore prednisolone's utility in other fields. The PRED-AID study is a randomized, cross-over trial comparing once-daily low-dose prednisolone to standard thrice-daily hydrocortisone for treating adrenal insufficiency, aiming to find a more convenient and potentially more physiologic replacement therapy. Other trials are investigating its use for unexplained recurrent pregnancy loss, its effect on uterine natural killer cells, and its potential to slow disease progression in infants with Duchenne muscular dystrophy.

IX. Expert Synthesis and Concluding Remarks

Integrated Benefit-Risk Assessment

Prednisolone's therapeutic profile is the quintessential "double-edged sword." Its profound and often life-saving benefits are derived from its potent, broad-spectrum anti-inflammatory and immunosuppressive actions, which are effective across an unparalleled range of diseases. This broad efficacy, however, is a direct result of its non-specific mechanism of action—the modulation of glucocorticoid receptors present in nearly every cell and tissue in the body. Consequently, its therapeutic effects are inextricably linked to a vast and predictable profile of adverse effects, ranging from metabolic and endocrine disturbances to psychiatric and musculoskeletal complications. The clinical decision to initiate prednisolone therapy is, therefore, a constant and dynamic assessment of this benefit-risk trade-off, a calculation that must be continuously re-evaluated and is heavily influenced by the intended dose, duration of treatment, and the specific vulnerabilities of the individual patient.

Summary of its Unwavering Position in Clinical Practice

Despite the passage of nearly 70 years since its introduction and the subsequent development of highly specific biologic agents and targeted small molecules, prednisolone remains an indispensable tool in the physician's armamentarium. Its low cost, oral bioavailability, rapid onset of action, and potent effects make it an irreplaceable first-line therapy for managing acute inflammatory flares and a reliable option for inducing remission in a wide variety of autoimmune diseases. Its role, far from diminishing, is evolving. Contemporary research highlights its critical function as a supportive care agent, enabling the use of modern immunotherapies by managing their treatment-related toxicities and serving as a cytotoxic backbone in combination chemotherapy regimens. This demonstrates a remarkable therapeutic longevity, where an old drug is not replaced but is instead integrated into the most advanced treatment paradigms.

Identification of Knowledge Gaps and Recommendations for Future Research

While much is known about prednisolone, several key areas warrant further investigation to optimize its use and minimize its harms.

• Personalized Dosing and Therapeutic Drug Monitoring: The documented high inter-patient pharmacokinetic variability, particularly in pediatric populations, suggests that standard weight-based dosing is a crude approach that can lead to suboptimal outcomes. Future research should focus on developing and validating biomarker-guided dosing strategies or implementing therapeutic drug monitoring to personalize therapy, ensuring adequate drug exposure while minimizing toxicity.
• Mechanisms of Tissue-Specific Action: A deeper understanding of the enzymatic processes that govern the interconversion between the prodrug prednisone and the active prednisolone in different tissues could be transformative. Research aimed at exploiting these tissue-specific metabolic pathways could lead to the development of novel corticosteroids or delivery systems with more localized activity, potentially achieving the long-sought goal of separating potent anti-inflammatory efficacy from systemic side effects.
• Optimization of irAE Management: The finding that high peak doses of corticosteroids are associated with worse survival in patients receiving immune checkpoint inhibitors is a critical observation that requires a shift in clinical practice. Prospective, randomized trials are urgently needed to define the minimum effective dose and duration of prednisolone for managing various irAEs and to rigorously evaluate the efficacy and safety of steroid-sparing alternative agents.
• Characterization of Long-Term, Low-Dose Safety: The GLORIA trial provided invaluable data on the safety of 5 mg/day of prednisolone in the elderly with RA. However, more long-term observational and interventional studies are needed across different diseases and age groups to fully characterize the cumulative risks associated with chronic low-dose (e.g., <5 mg/day) therapy, which is a common but poorly understood clinical scenario. This will allow for more informed long-term treatment decisions and better patient counseling.

Works cited

1. Prednisolone - Wikipedia, accessed July 11, 2025, https://en.wikipedia.org/wiki/Prednisolone
2. Prednisolone | C21H28O5 | CID 5755 - PubChem, accessed July 11, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Prednisolone
3. What is the mechanism of Prednisone? - Patsnap Synapse, accessed July 11, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-prednisone/
4. Prednisone - StatPearls - NCBI Bookshelf, accessed July 11, 2025, https://www.ncbi.nlm.nih.gov/books/NBK534809/
5. Prednisolone - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Renal Dose, Hepatic Dose | Drug Index | Pediatric Oncall, accessed July 11, 2025, https://www.pediatriconcall.com/drugs/prednisolone/891
6. Prednisolone | CAS 50-24-8 | SCBT - Santa Cruz Biotechnology, accessed July 11, 2025, https://www.scbt.com/p/prednisolone-50-24-8
7. Prednisolone: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed July 11, 2025, https://go.drugbank.com/drugs/DB00860
8. www.nhs.uk, accessed July 11, 2025, https://www.nhs.uk/medicines/prednisolone/about-prednisolone-tablets-and-liquid/#:~:text=Prednisolone%20is%20a%20medicine%20used,calm%20down%20your%20immune%20system.
9. CAS Number 50-24-8 | Prednisolone - Spectrum Chemical, accessed July 11, 2025, https://www.spectrumchemical.com/cas/50-24-8
10. Prednisolone (NSC 9120, NSC 9900, CAS Number: 50-24-8) | Cayman Chemical, accessed July 11, 2025, https://www.caymanchem.com/product/20866/prednisolone
11. Pharmacokinetics and pharmacodynamics of three different prednisolone prodrugs: effect on circulating lymphocyte subsets and function. - AAI Journals, accessed July 11, 2025, https://journals.aai.org/jimmunol/article/133/5/2479/16575/Pharmacokinetics-and-pharmacodynamics-of-three
12. Side effects of prednisolone tablets and liquid - NHS, accessed July 11, 2025, https://www.nhs.uk/medicines/prednisolone/side-effects-of-prednisolone-tablets-and-liquid/
13. Treatment with Prednisolone Tablets, accessed July 11, 2025, https://mft.nhs.uk/app/uploads/sites/2/2018/04/REH-083.pdf
14. Prednisone | C21H26O5 | CID 5865 - PubChem, accessed July 11, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Prednisone
15. Reactome/PharmGKB collaboration: Prednisone and Prednisolone Pathway, Pharmacokinetics, accessed July 11, 2025, https://www.pharmgkb.org/pathway/PA166273601
16. Open-label, single dose pharmacokinetic study of prednisolone at steady state in young patients with SLE on prednisone therapy, accessed July 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3742043/
17. What are the pharmacokinetics of Prednisone (corticosteroid)? - Dr.Oracle AI, accessed July 11, 2025, https://www.droracle.ai/articles/76737/what-are-the-pharmacokinetics-of-prednisone-corticosteroid
18. Prednisone Uses, Dosage, Side Effects, Warnings - Drugs.com, accessed July 11, 2025, https://www.drugs.com/prednisone.html
19. 11 Prednisone Interactions and How to Manage Them - GoodRx, accessed July 11, 2025, https://www.goodrx.com/prednisone/interactions
20. About prednisolone tablets and liquid - NHS, accessed July 11, 2025, https://www.nhs.uk/medicines/prednisolone/about-prednisolone-tablets-and-liquid/
21. prednisolone: Dosing, contraindications, side effects, and pill pictures - epocrates online, accessed July 11, 2025, https://www.epocrates.com/online/drugs/65/prednisolone
22. Prednisolone: Side effects, dosage, uses, and more, accessed July 11, 2025, https://www.medicalnewstoday.com/articles/drugs-prednisolone-oral-forms
23. Orapred ODT® (prednisolone sodium phosphate orally disintegrating tablets) - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed July 11, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021959s004lbl.pdf
24. Prednisone: MedlinePlus Drug Information, accessed July 11, 2025, https://medlineplus.gov/druginfo/meds/a601102.html
25. Crohn's disease - Diagnosis and treatment - Mayo Clinic, accessed July 11, 2025, https://www.mayoclinic.org/diseases-conditions/crohns-disease/diagnosis-treatment/drc-20353309
26. Pediapred, Orapred (prednisolone) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed July 11, 2025, https://reference.medscape.com/drug/pediapred-orapred-prednisolone-342745
27. prednisolone Clinical Research Trials | CenterWatch, accessed July 11, 2025, https://www.centerwatch.com/clinical-trials/listings/search/?q=prednisolone
28. Results of a 6-week treatment with 10 mg prednisolone in patients with hand osteoarthritis (HOPE): a double-blind, randomised, placebo-controlled trial - PubMed, accessed July 11, 2025, https://pubmed.ncbi.nlm.nih.gov/31727410/
29. A randomized, double-blind, placebo-controlled trial of low-dose ..., accessed July 11, 2025, https://pubmed.ncbi.nlm.nih.gov/22956551/
30. Effect of prednisolone on live birth rate in women with unexplained recurrent pregnancy loss, accessed July 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12182118/
31. Prednisone and Prednisolone for Dogs and Cats - PetMD, accessed July 11, 2025, https://www.petmd.com/pet-medication/prednisone-and-prednisolone-for-dogs-cats
32. www.nhs.uk, accessed July 11, 2025, https://www.nhs.uk/medicines/prednisolone/#:~:text=Brand%20names%3A%20Deltacortril%2C%20Deltastab%2C,and%20how%20to%20take%20it.
33. Popular Corticosteroids List, Drug Prices and Medication Information - GoodRx, accessed July 11, 2025, https://www.goodrx.com/classes/corticosteroids
34. FDA approves prednisolone acetate ophthalmic suspension for treating steroid-responsive ocular inflammation - Ophthalmology Times, accessed July 11, 2025, https://www.ophthalmologytimes.com/view/fda-approves-prednisolone-acetate-ophthalmic-suspension-for-treating-steroid-responsive-ocular-inflammation
35. Prednisolone (International database) - Drugs.com, accessed July 11, 2025, https://www.drugs.com/international/prednisolone.html
36. Steroids - Information for patients, relatives and carers - Imperial College Healthcare NHS Trust, accessed July 11, 2025, https://www.imperial.nhs.uk/~/media/website/services/cancer-services/neuro-oncology/steroids.pdf
37. Short-term steroid treatment | Great Ormond Street Hospital, accessed July 11, 2025, https://www.gosh.nhs.uk/conditions-and-treatments/medicines-information/short-term-steroid-treatment/
38. Long- and Short-Term Prednisone Side Effects You Should Know - GoodRx, accessed July 11, 2025, https://www.goodrx.com/prednisone/what-do-i-need-to-know-before-taking-prednisone
39. Prednisolone - East Kent Hospitals, accessed July 11, 2025, https://mgdm.ekhuft.nhs.uk/documents/download/prednisolone-patient-information-leaflet
40. Corticosteroids - StatPearls - NCBI Bookshelf, accessed July 11, 2025, https://www.ncbi.nlm.nih.gov/books/NBK554612/
41. Who can and cannot take prednisolone tablets and liquid - NHS, accessed July 11, 2025, https://www.nhs.uk/medicines/prednisolone/who-can-and-cannot-take-prednisolone-tablets-and-liquid/
42. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study | The BMJ, accessed July 11, 2025, https://www.bmj.com/content/357/bmj.j1415
43. Prednisolone: a steroid to treat allergies and infections - HSE.ie, accessed July 11, 2025, https://www2.hse.ie/medicines/prednisolone/
44. Prednisolone Interactions Checker - Drugs.com, accessed July 11, 2025, https://www.drugs.com/drug-interactions/prednisolone.html
45. Taking prednisolone with other medicines and herbal supplements - NHS, accessed July 11, 2025, https://www.nhs.uk/medicines/prednisolone/taking-prednisolone-with-other-medicines-and-herbal-supplements/
46. Drug Approval Package: Prednisolone NDA #075250, accessed July 11, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/075250_PrednisoloneTOC.cfm
47. Orapred ODT (prednisolone sodium phosphate) FDA Approval History - Drugs.com, accessed July 11, 2025, https://www.drugs.com/history/orapred-odt.html
48. Flo-Pred (prednisolone acetate) FDA Approval History - Drugs.com, accessed July 11, 2025, https://www.drugs.com/history/flo-pred.html
49. Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension, accessed July 11, 2025, https://investors.amneal.com/news/press-releases/press-release-details/2025/Amneal-Receives-U-S--FDA-Approval-for-Prednisolone-Acetate-Ophthalmic-Suspension/default.aspx
50. Prednisolone | 50-24-8 supplier and manufacturer - BuyersGuideChem, accessed July 11, 2025, https://www.buyersguidechem.com/chemical_supplier/Prednisolone
51. Prednisolone API Suppliers - Find All GMP Manufacturers - Pharmaoffer.com, accessed July 11, 2025, https://pharmaoffer.com/api-excipient-supplier/corticosteroids/prednisolone
52. Prednisolone Base - Axplora, accessed July 11, 2025, https://www.axplora.com/api-product/50-24-8-ss/
53. Global Corticosteroids API Competitive Landscape Professional Research Report 2025, accessed July 11, 2025, https://www.marketresearch.com/Deep-Insights-Research-Co-DIR-v4285/Global-Corticosteroids-API-Competitive-Landscape-39402882/
54. Generic PREDNISOLONE SODIUM PHOSPHATE INN entry, pharmaceutical patent and freedom to operate - DrugPatentWatch, accessed July 11, 2025, https://www.drugpatentwatch.com/p/generic-api/PREDNISOLONE+SODIUM+PHOSPHATE
55. Search Results for prednisone - DailyMed, accessed July 11, 2025, https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=prednisone
56. Prednisone Tablets, USP - USA, accessed July 11, 2025, https://www.tevausa.com/our-products/tevagenerics/teva-generics-catalog/vision-product-page/prednisonetabletsusp
57. Drug Shortage Detail: Prednisone Oral Tablets - ASHP, accessed July 11, 2025, https://www.ashp.org/drug-shortages/current-shortages/drug-shortage-detail.aspx?id=563
58. Prednisone Tablets – Manufacturer - AdvaCare Pharma, accessed July 11, 2025, https://www.advacarepharma.com/en/pharmaceuticals/prednisone-tablets
59. Prednisolone Tablets – Manufacturer - AdvaCare Pharma, accessed July 11, 2025, https://www.advacarepharma.com/en/pharmaceuticals/prednisolone-tablets
60. Corticosteroids Companies - Top Company List - Mordor Intelligence, accessed July 11, 2025, https://www.mordorintelligence.com/industry-reports/corticosteroids/companies
61. Suppliers for Prednisolone 5mg tablets - dm+d browser, accessed July 11, 2025, https://dmd-browser.nhsbsa.nhs.uk/vmp/view/202/suppliers?ref=
62. Low dose, add-on prednisolone in patients with rheumatoid arthritis ..., accessed July 11, 2025, https://pubmed.ncbi.nlm.nih.gov/35641125/
63. Efficacy and safety of 10 mg versus 30 mg of oral prednisolone for ..., accessed July 11, 2025, https://pubmed.ncbi.nlm.nih.gov/39412710/
64. Clinical Trials Using Prednisolone - NCI, accessed July 11, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/prednisolone?pn=1
65. Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials - ASCO Publications, accessed July 11, 2025, https://ascopubs.org/doi/abs/10.1200/JCO.24.00191
66. Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials - PubMed, accessed July 11, 2025, https://pubmed.ncbi.nlm.nih.gov/39110922/
67. Safety and Efficacy of Prednisolone in Adrenal Insufficiency Disease (PRED-AID Study), accessed July 11, 2025, https://clinicaltrials.gov/study/NCT03936517